Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity

Journal of Immunology

Volumn 170, Issue 3, 2003, Pages 1209-1217

  Rubinstein, Mark P ^a   Kadima, Andre N ^a   Salem, Mohamed L ^a   Nguyen, Christophe L ^a   Gillanders, William E ^a   Nishimura, Michael I ^b   Cole, David J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; GENE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 0037309288     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.3.1209     Document Type: Article

References (88)

1. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N. Engl. J. Med. 319:1676.
2. Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1159.
3. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038.
4. Mackinnon, S., E. B. Papadopoulos, M. H. Carabasi, L. Reich, N. H. Collins, F. Boulad, H. Castro-Malaspina, B. H. Childs, A. P. Gillio, N. A. Kernan, et al. 1995. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261.
5. Papadopoulos, E. B., M. Ladanyi, D. Emanuel, S. Mackinnon, F. Boulad, M. H. Carabasi, H. Castro-Malaspina, B. H. Childs, A. P. Gillio, T. N. Small, et al. 1994. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330:1185.
6. Collins, R. H., Jr., O. Shpilberg, W. R. Drobyski, D. L. Porter, S. Giralt, R. Champlin, S. A. Goodman, S. N. Wolff, W. Hu, C. Verfaillie, et al. 1997. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15:433.
7. Kessels, H. W., M. C. Wolkers, and T. N. Schumacher. 2002. Adoptive transfer of T-cell immunity. Trends Immunol. 23:264.
8. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 19:19.
9. Rosenberg, S. A. 1992. Karnofsky Memorial Lecture: the immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10:180.
10. Strand, S., W. J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-I/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat. Med. 2:1361.
11. Schwartz, R. H. 1990. A cell culture model for T lymphocyte clonal anergy. Science 248:1349.
12. Ochsenbein, A. F., P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner, and R. M. Zinkernagel. 1999. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 96:2233.
13. Smyth, M. J., D. I. Godfrey, and J. A. Trapani. 2001. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2:293.
14. Levitsky, H. I. 2000. Augmentation of host immune responses to cancer: overcoming the barrier of tumor antigen-specific T-cell tolerance. Cancer J. Sci. Am. 6(Suppl. 3):S281.
15. Liu, X., E. A. Peralta, J. D. Ellenhorn, and D. J. Diamond. 2000. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells. Cancer Res. 60:693.
16. Colella, T. A., T. N. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard. 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 191:1221.
17. Zeh, H. J. III, D. Perry-Lalley, M. E. Dudley, S. A. Rosenberg, and J. C. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162:989.
18. Kessels, H. W., M. D. van Den Boom, H. Spits, E. Hooijberg, and T. N. Schumacher. 2000. Changing T cell specificity by retroviral T cell receptor display. Proc. Natl. Acad. Sci. USA 97:14578.
19. Cole, D. J., D. P. Weil, J. Shilyansky, M. Custer, Y. Kawakami, S. A. Rosenberg, and M. I. Nishimura. 1995. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-I melanoma antigen. Cancer Res. 55:748.
20. Mouri, T., S. Nakamura, Y. Ohyama, G. Matsuzaki, M. Shinohara, K. Kishihara, A. Hiroki, M. Oka, K. Shirasuna, and K. Nomoto. 1996. T cell receptor Vα and Vβ gene usage by tumour-infiltrating lymphocytes in oral squamous cell carcinoma. Cancer Immunol. Immunother. 43:10.
21. Shilyansky, J., M. I. Nishimura, J. R. Yannelli, Y. Kawakami, L. S. Jacknin, P. Charmley, and S. A. Rosenberg. 1994. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proc. Natl. Acad. Sci. USA 91:2829.
22. Dietrich, P. Y., P. R. Walker, A. L. Quiquerez, G. Perrin, V. Dutoit, D. Lienard, P. Guillaume, J. C. Cerottini, P. Romero, and D. Valmori. 2001. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res. 61:2047.
23. Renkvist, N., C. Castelli, P. F. Robbins, and G. Parmiani. 2001. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50:3.
24. Davis, M. M. 1990. T cell receptor gene diversity and selection. Annu. Rev. Biochem. 59:475.
25. Sha, W. C., C. A. Nelson, R. D. Newberry, D. M. Kranz, J. H. Russell, and D. Y. Loh. 1988. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature 335:271.
26. + T cells in transgenic mice expressing a class II MHC-restricted antigen receptor. Nature 341:746.
27. Dembic, Z., W. Haas, S. Weiss, J. McCubrey, H. Kiefer, H. von Boehmer, and M. Steinmetz. 1986. Transfer of specificity by murine α and β T-cell receptor genes. Nature 320:232.
28. Fujio, K., Y. Misaki, K. Setoguchi, S. Morita, K. Kawahata, I. Kato, T. Nosaka, K. Yamamoto, and T. Kitamura. 2000. Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the αβ TCR complex. J. Immunol. 165:528.
29. Clay, T. M., M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura. 1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163:507.
30. Cooper, L. J., M. Kalos, D. A. Lewinsohn, S. R. Riddell, and P. D. Greenberg. 2000. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74:8207.
31. Uematsu, Y., S. Ryser, Z. Dembic, P. Borgulya, P. Krimpenfort, A. Berns, H. von Boehmer, and M. Steinmetz. 1988. In transgenic mice the introduced functional T cell receptor β gene prevents expression of endogenous β genes. Cell 52:831.
32. Borgulya, P., H. Kishi, Y. Uematsu, and H. von Boehmer. 1992. Exclusion and inclusion of α and β T cell receptor alleles. Cell 69:529.
33. Dahl, A. M., P. C. Beverley, and H. J. Stauss. 1996. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J. Immunol. 157:239.
34. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93:4102.
35. Dutoit, V., V. Rubio-Godoy, P. Y. Dietrich, A. L. Quiqueres, V. Schnuriger, D. Rimoldi, D. Lienard, D. Speiser, P. Guillaume, P. Batard, et al. 2001. Heterogeneous T-cell response to MAGE-A 10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res. 61:5850.
36. Kelly, J. M., S. J. Sterry, S. Cose, S. J. Turner, J. Fecondo, S. Rodda, P. J. Fink, and F. R. Carbone. 1993. Identification of conserved T cell receptor CDR3 residues contacting known exposed peptide side chains from a major histocompatibility complex class I-bound determinant. Eur. J. Immunol. 23:3318.
37. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17.
38. Clarke, S. R., M. Barnden, C. Kurts, F. R. Carbone, J. F. Miller, and W. R. Heath. 2000. Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol. Cell Biol. 78:110.
39. Orentas, R. J., S. J. Roskopf, G. P. Nolan, and M. I. Nishimura. 2001. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin. Immunol. 98:220.
40. Kessels, H. W., M. C. Wolkers, M. D. van den Boom, M. A. van der Valk, and T. N. Schumacher. 2001. Immunotherapy through TCR gene transfer. Nat. Immunol. 2:957.
41. Stanislawski, T., R. H. Voss, C. Lotz, E. Sadovnikova, R. A. Willemsen, J. Kuball, T. Ruppert, R. L. Bolhuis, C. J. Melief, C. Huber, et al. 2001. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2:962.
42. Zebedee, S. L., D. Barritt, R. Epstein, and W. C. Raschke. 1991. Analysis of Ly5 chromosome 1 position using allelic differences and recombinant inbred mice. Eur. J. Immunogenet. 18:155.
43. Shevach, E. M., J. D. Stobo, and I. Green. 1972. Immunoglobulin and τ-bearing murine leukemias and lymphomas. J. Immunol. 108:1146.
44. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54:777.
45. Stotz, S. H., L. Bolliger, F. R. Carbone, and E. Palmer. 1999. T cell receptor (TCR) antagonism without a negative signal: evidence from T cell hybridomas expressing two independent TCRs. J. Exp. Med. 189:253.
46. Treisman, J., P. Hwu, S. Minamoto, G. E. Shafer, R. Cowherd, R. A. Morgan, and S. A. Rosenberg. 1995. lnterleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 85:139.
47. Markowitz, D., S. Goff, and A. Bank. 1988. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62:1120.
48. Crossland, K. D., V. K. Lee, W. Chen, S. R. Riddell, P. D. Greenberg, and M. A. Cheever. 1991. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J. Immunol. 146:4414.
49. + T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation. Clin. Cancer Res. 5:461.
50. Yoshizawa, H., A. E. Chang, and S. Shu. 1991. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 147:729.
51. Yoshizawa, H., K. Sakai, A. E. Chang, and S. Y. Shu. 1991. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell. Immunol. 134:473.
52. Nguyen, C. L., J. T. Bui, M. Demcheva, J. N. Vournakis, D. J. Cole, and W. E. Gillanders. 2001. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response. J. Immunother. 24:420.
53. Mattis, A. E., G. Bernhardt, M. Lipp, and R. Forster. 1997. Analyzing cytotoxic T lymphocyte activity: a simple and reliable flow cytometry-based assay. J. Immunol. Methods 204:135.
54. King, M. A. 2000. Detection of dead cells and measurement of cell killing by flow cytometry. J. Immunol. Methods 243:155.
55. Letourneur, F., and B. Malissen. 1989. Derivation of a T cell hybridoma variant deprived of functional T cell receptor α and β chain transcripts reveals a nonfunctional α-mRNA of BW5I47 origin. Eur. J. Immunol. 19:2269.
56. Manolios, N., F. Letoumeur, J. S. Bonifacino, and R. D. Klausner. 1991. Pairwise, cooperative and inhibitory interactions describe the assembly and probable structure of the T-cell antigen receptor. EMBO J. 10:1643.
57. Labrecque, N., L. S. Whitfield, R. Obst, C. Waltzinger, C. Benoist, and D. Mathis. 2001. How much TCR does a T cell need? Immunity 15:71.
58. Jorgensen, J. L., U. Esser, B. Fazekas de St Groth, P. A. Reay, and M. M. Davis. 1992. Mapping T-cell receptor-peptide contacts by variant peptide immunization of single-chain transgenics. Nature 355:224.
59. + T cell subpopulations in established pulmonary metastases. J. Immunol. 162:6671.
60. Kemp, R. A., and F. Ronchese. 2001. Tumor-specific tc1, but not tc2, cells deliver protective antitumor immunity. J. Immunol. 167:6497.
61. b major histocompatibility complex class I molecule to alloreactive T cells. J. Exp. Med. 182:1739.
62. + IL-2-stimulated murine killer cells: in vitro generation and in vivo antitumor activity. J. Immunol. 142:1383.
63. Lauwerys, B. R., N. Garot, J. C. Renauld, and F. A. Houssiau. 2000. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J. Immunol. 165:1847.
64. + lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol. Immunother. 51:440.
65. Stankova, J., D. W. Hoskin, and J. C. Roder. 1989. Murine anti-CD3 monoclonal antibody induces potent cytolytic activity in both T and NK cell populations. Cell. Immunol. 121:13.
66. Massaro, A. F., D. D. Schoof, A. Rubinstein, M. Zuber, F. J. Leonard-Vidal, and T. J. Eberlein. 1990. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes. Cancer Res. 50:2587.
67. Leeuwenberg, J. F., H. Spits, W. J. Tax, and P. J. Capel. 1985. Induction of nonspecific cytotoxicity by monoclonal anti-T3 antibodies. J. Immunol. 134:3770.
68. + T cells can be distinguished by their cytokine profiles and phenotypic markers. J. Immunol. 164:208.
69. + T cells. Nature 401:76.
70. Pogulis, R. J., M. J. Hansen, and L. R. Pease. 1998. Retroviral-mediated expression of an MHC class I-restricted T cell receptor in the CD8 T cell compartment of bone marrow-reconstituted mice. Hum. Gene Ther. 9:2285.
71. Clay, T. M., M. C. Custer, P. J. Spiess, and M. I. Nishimura. 1999. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Pathol. Oncol. Res. 5:3.
72. Schumacher, T. N. 2002. T-cell-receptor gene therapy. Nat. Rev. Immunol. 2:512.
73. Clay, T. M., M. Morse, and H. K. Lyerly. 2002. Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes. Expert Opin. Biol. Ther. 2:353.
74. + T lymphocyte differentiation as a mechanism for subdominant cytotoxic T lymphocyte responses to a viral antigen. J. Exp. Med. 191:1687.
75. + T lymphocytes involving loss of tetramer labeling. Eur. J. Immunol. 32:1688.
76. + tumor-infiltrating lymphocytes. J. Exp. Med. 173:647.
77. Aruga, A., S. Shu, and A. E. Chang. 1995. Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon γ secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol. Immunother. 41:317.
78. Schwartzentruber, D. J., S. S. Hom, R. Dadmarz, D. E. White, J. R. Yannelli, S. M. Steinberg, S. A. Rosenberg, and S. L. Topalian. 1994. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J. Clin. Oncol. 12:1475.
79. Packard, B. Z., and A. Komoriya. 1998. Tumor cell recognition by lymphocytes: is the MHC always essential? Crit. Rev. Immunol. 18:139.
80. + T cells without selection of higher affinity TCR. Nat. Immunol. 2:711.
81. Fahmy, T. M., J. G. Bieler, M. Edidin, and J. P. Schneck. 2001. Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity 14:135.
82. + T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC. J. Immunol. 165:6731.
83. Rosette, C., G. Werlen, M. A. Daniels, P. O. Holman, S. M. Alam, P. J. Travers, N. R. Gascoigne, E. Palmer, and S. C. Jameson. 2001. The impact of duration versus extent of TCR occupancy on T cell activation: a revision of the kinetic proofreading model. Immunity 15:59.
84. Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160:643.
85. Alexander-Miller, M. A., G. R. Leggatt, A. Sarin, and J. A. Berzofsky. 1996. Role of antigen, CDS, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184:485.
86. Bachmann, M. F., M. Barner, A. Viola, and M. Kopf. 1999. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur. J. Immunol. 29:291.
87. Shusta, E. V., P. D. Holler, M. C. Kieke, D. M. Kranz, and K. D. Wittrup. 2000. Directed evolution of a stable scaffold for T-cell receptor engineering. Nat. Biotechnol. 18:754.
88. Weidanz, J. A., K. F. Card, A. Edwards, E. Perlstein, and H. C. Wong. 1998. Display of functional αβ single-chain T-cell receptor molecules on the surface of bacteriophage. J. Immunol. Methods 221:59.